Program
naperiglipron
Also written as “LY3549492” and “[14C]-LY3549492”.
In Eli Lilly’s own words, LY3549492 (Naperiglipron) is a chemical entity that acts as an agonist for the glucagon-like peptide-1 (GLP-1) receptor.
. Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Body Weight, led by Eli Lilly.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 101 open or running | phase 2since Nov 6, 2023 | Feb 16, 2021 | Sep 2027phase 2 · NCT06143956 |
- Named in Eli Lilly’s own pipeline as
Naperiglipron
, phase 2, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 16, 2021First study: phase 1 study in HealthyFirst studyNCT04758234 · 54 enrolled · United States
- Apr 8, 2022Phase 1 study in Diabetes Mellitus, Type 2NCT05327595 · 80 enrolled · Germany
- Nov 6, 2023Phase 2 study in ObesityNCT06143956 · 1,481 planned · United States, Argentina
- Dec 20, 2023Phase 1 study in Healthy MaleNCT06194500 · 18 enrolled · United Kingdom
- Nov 8, 2024Phase 2 study in ObesityNCT06683508 · 288 enrolled · United States
- Mar 10, 2025Phase 1 study in Diabetes Mellitus, Type 2NCT06869018 · 92 enrolled · Japan
- Jun 13, 2025Phase 2 study in ObesityNCT07030868 · 1 enrolled · United States, Argentina
- Jul 10, 2025Phase 1 study in Diabetes Mellitus, Type 2NCT07073170 · 36 enrolled · China
- Jul 18, 2025Phase 2 study in Body WeightNCT07085468 · 1 enrolled · United States, Canada
- Nov 14, 2025Phase 1 study in ObesityNCT07232732 · 120 enrolled · United States
Ahead
- Sep 2027Primary completion: phase 2 study in ObesityNCT06143956
TargetBeta
“LY3549492 (Naperiglipron) is a chemical entity that acts as an agonist for the glucagon-like peptide-1 (GLP-1) receptor.”company, read by Claude · source
Other programs on GLP1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Semaglutiderule | Novo Nordisk | phase 4 | 170 |
| Liraglutiderule | Novo Nordisk | phase 4 | 116 |
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| dulaglutiderule | Eli Lilly | phase 4 | 47 |
| orforglipronrule | Eli Lilly | phase 3 | 50 |
| survodutide | Boehringer Ingelheim | phase 3 | 35 |
| zenagamtide | Novo Nordisk | phase 3 | 35 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| mazdutiderule | Innovent Biologics | phase 3 | 27 |
| bofanglutiderule | Gan & Lee Pharmaceuticals | phase 3 | 25 |
| berobenatide | Pfizer | phase 3 | 23 |
| brenipatide | Eli Lilly | phase 3 | 19 |
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07232732Obesity · United States | 1 | Completed | Jul 17, 2026 | 120 |
| NCT07085468Body Weight · United States, Canada | 2 | Terminated | Aug 14, 2025 | 1 |
| NCT07073170Diabetes Mellitus, Type 2 · China | 1 | Completed | Jan 27, 2026 | 36 |
| NCT07030868Obesity · United States, Argentina | 2 | Terminated | Jul 29, 2025 | 1 |
| NCT06869018Diabetes Mellitus, Type 2 · Japan | 1 | Completed | Mar 2, 2026 | 92 |
| NCT06683508Obesity · United States | 2 | Completed | Jan 7, 2026 | 288 |
| NCT06194500Healthy Male · United Kingdom | 1 | Completed | Feb 15, 2024 | 18 |
| NCT06143956Obesity · United States, Argentina | 2 | Recruiting | Sep 2027 | 1,481 |
| NCT05327595Diabetes Mellitus, Type 2 · Germany | 1 | Completed | Apr 22, 2024 | 80 |
| NCT04758234Healthy · United States | 1 | Completed | Jan 10, 2022 | 54 |
How it is read
Names in the registry
- “LY3549492”, 10 entries
- “[14C]-LY3549492”, 2 entries
Conditions, from the studies’ own filings
- Obesity, 4 studies
- Diabetes Mellitus, Type 2, 3 studies
- Body Weight, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.